Key Development
AstraZeneca is not simply adding a MET inhibitor to Tagrisso. It is attempting to extend the treatment life cycle of the same patient by targeting the resistance mechanism that emerges after EGFR therapy.
On September 29, 2026, HUTCHMED announced that AstraZeneca had submitted a U.S. NDA for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in locally advanced or metastatic NSCLC with MET overexpression or amplification after progression on or following EGFR-TKI therapy. Savolitinib is an oral selective MET inhibitor discovered by HUTCHMED and jointly developed with AstraZeneca.
The filing is supported by the global Phase 3 SAFFRON study, where the combination produced statistically significant and clinically meaningful improvements in both progression-free and overall survival compared with platinum-doublet chemotherapy. Importantly, only high-level results have been disclosed so far; numerical hazard ratios and median PFS/OS are expected at ESMO 2026 in October.
Why It Matters
- MET is an important route of resistance to osimertinib. Earlier FLAURA analyses identified MET amplification in approximately 15% of patients with progression after first-line Tagrisso, while broader estimates for post-osimertinib MET aberration vary substantially by assay and definition.
- The strategy treats resistance biology instead of immediately defaulting to chemotherapy. Patients remain on EGFR blockade while savolitinib targets the MET escape pathway.
- The approach already has clinical validation in China. The ORPATHYS–TAGRISSO combination was approved there in 2025 for MET-amplified disease after EGFR-TKI progression based on SACHI, which reported a 66% reduction in the risk of progression or death versus platinum chemotherapy.
- AstraZeneca is already testing the concept earlier. The SANOVO Phase 3 trial in China also reported a significant PFS benefit for first-line Tagrisso plus Orpathys in EGFR-mutated, MET-overexpressing disease.
Healthcare Insight Analysis
Healthcare Insight believes the most strategically important asset in this filing may not be savolitinib itself.
It is the Tagrisso franchise architecture.
Tagrisso already spans metastatic first-line disease, chemotherapy combinations, adjuvant treatment and unresectable Stage III EGFR-mutated NSCLC. This new filing potentially extends that architecture into another clinically important point: MET-driven progression after EGFR-targeted therapy.
The commercial logic is increasingly clear:
EGFR mutation → Tagrisso → progression → molecular reassessment → MET-driven resistance → retain Tagrisso and add ORPATHYS.
Instead of allowing progression to remove a patient from the franchise, AstraZeneca is attempting to turn progression into a new biomarker-defined treatment opportunity.
That reflects a larger change in precision oncology.
Drug resistance is increasingly being treated not as a generic endpoint where targeted therapy has “stopped working,” but as a new biological state that can be profiled and therapeutically attacked.
The principal bottleneck, however, may be diagnostics rather than pharmacology.
MET amplification and MET protein overexpression are not interchangeable concepts. HUTCHMED has previously estimated that 15–50% of patients progressing after osimertinib may show some form of MET aberration, but prevalence depends strongly on sample type, testing methodology and assay cutoff.
That wide range matters commercially.
If FDA ultimately approves the regimen, real-world uptake will depend on whether oncologists know when to re-biopsy, which assay to use, how MET positivity is defined and whether payers reimburse repeat molecular testing.
In other words, the addressable market will not simply equal the number of patients who progress on Tagrisso. It will equal the number who are successfully retested, classified as MET-driven and able to access the combination.
There is also a competitive issue.
The post-EGFR progression market is becoming crowded with EGFR/MET-directed regimens and other biomarker-driven strategies. ORPATHYS + TAGRISSO therefore needs more than biological logic. It must demonstrate that survival benefit, oral administration and tolerability together create a sufficiently attractive treatment profile.
Market Implications
AstraZeneca: approval could extend Tagrisso’s commercial life by maintaining osimertinib as the backbone even after disease progression.
HUTCHMED: a U.S. approval would represent major global validation for a China-discovered molecule. AstraZeneca leads development outside China and global commercialization, while HUTCHMED is eligible for milestones and royalties.
Diagnostics companies: MET testing could become a significant beneficiary as repeat molecular profiling moves from informative testing toward a direct treatment gatekeeper.
Oncology centers: resistance profiling and re-biopsy may need to become a routine part of the EGFR-mutated NSCLC pathway rather than a one-time diagnostic event.
ANALYTICAL MATRIX
| Dimension | Current Signal | Opportunity | Key Risk |
| Clinical | SAFFRON positive for PFS and OS | Chemo-free post-EGFR option | Full numerical data pending |
| Biology | Targets MET-driven resistance | Treat the mechanism of escape | MET definitions vary |
| Franchise | Tagrisso remains backbone | Extend patient lifetime within franchise | Increasing combination competition |
| Diagnostics | MET testing required | Growth in repeat profiling | Assay and cutoff fragmentation |
| HUTCHMED | China-discovered asset reaches U.S. filing | Global validation and royalties | Regulatory approval still pending |
The next two signals matter most: the full SAFFRON dataset at ESMO 2026, and how MET overexpression/amplification is ultimately defined for regulatory and diagnostic use if FDA reviews and approves the application.
If the combination reaches the U.S. market, its significance will extend beyond one new lung-cancer regimen: EGFR resistance will increasingly become not the end of targeted therapy, but the starting point for the next round of precision treatment.